The trajectory of companies tied to Sildenafil's past presents a complex investment picture . While the initial surge generated substantial profits , generic competition have significantly eroded sales . Investing in associated pharmaceutical firms now requires a careful assessment of patent safeguards, evolving healthcare shifts , and the potentia